Pfizer’s coronavirus vaccine is more than 90% effective, early data suggests
Early data suggests that Pfizer’s coronavirus vaccine is more than 90% effective in preventing an infection with the virus that […]
A volunteer participating in clinical trials of the COVID-19 vaccine developed by Oxford University has died in Brazil, officials said […] Scientists called for urgent action to improve public trust in immunisation as research suggested sizeable minorities in some nations may […] NEW YORK and MAINZ, GERMANY, October 6, 2020 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation […] Trump blasts Biden over COVID: ‘He’ll close down the whole country’ President claims former VP will destroy America by not […] Giving the HPV vaccine to schoolgirls slashes their risk of getting cervical cancer by 88%, major study claims The Swedish […] WEDNESDAY, Sept. 23, 2020 — Stricter guidelines for emergency authorization use of a vaccine against the new coronavirus could soon […] Washington University School of Medicine is helping lead an ambitious, worldwide study to see if giving adults the measles, mumps […] Russia said on Thursday it would start clinical trials of its controversial coronavirus vaccine next week, involving tens of thousands […] (HealthDay)—A vaccine based on cutting-edge RNA gene technology showed promising potency against the new coronavirus in an early trial, scientists […]vaccine
Volunteer in Oxford COVID vaccine test dies in Brazil: officials
Scientists raise alarm over signs of vaccine ‘hesitancy’
BioNTech and Pfizer Initiate Rolling Submission to European Medicines Agency for SARS-CoV-2 Vaccine Candidate BNT162b2
Moderna's coronavirus vaccine won't be ready for widespread distribution until spring, CEO predicts
Giving HPV vaccine to girls 'cuts risk of cervical cancer by 88%'
Stricter Vaccine Approval Rules Coming From FDA
Could common vaccine given to kids help prevent COVID-19 in adults?
Russia to test coronavirus vaccine on 40,000 people
Pfizer’s COVID vaccine shows ‘robust’ results in early trial